MiR-1976 knockdown promotes epithelial–mesenchymal transition and cancer stem cell properties inducing triple-negative breast cancer metastasis

Jingyi Wang1,2, Minghui Li1,2, Xu Han1, Hui Wang1, Xinyang Wang1, Ge Ma1,2, Tiansong Xia1,2 and Shui Wang1,2

Abstract
Triple-negative breast cancer (TNBC), characterized by high aggression and invasiveness, has a worse prognosis than other subtypes of breast cancer. Establishing a novel animal model is helpful to understand the mechanisms involved in the progress of TNBC metastasis. In a self-established mouse model consisting of normal human breast tissues and normal human bone tissues, TNBC cell line SUM-1315 could spontaneously form species-specific bone metastasis. The expression level of miR-1976 in SUM-1315-bo (derived from metastatic bone tumor) was found lower than that in SUM-1315-br (derived from orthotopic breast tumor). MiR-1976 was found to be downregulated in TNBC tissues, and lower expression of miR-1976 was correlated with worse overall survival in a patient cohort obtained from TCGA database. MiR-1976 knockdown promoted epithelial–mesenchymal transition (EMT) and cancer stem cell (CSC) properties in vitro and in vivo. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG) was verified as a target gene by sequencing, biotinylated miRNA pull-down, and luciferase reporter assay. Moreover, overexpression and suppression analysis implicated PIK3CG as a mediator of the biological effects of miR-1976. Our study demonstrated that miR-1976 knockdown could promote EMT and CSCs by PIK3CG. These findings may reveal mechanisms of TNBC metastasis, and represent a potential treatment target for patients with TNBC.

Introduction
Triple-negative breast cancer (TNBC), characterized by high aggression and invasiveness, is an unsolved difficulty in treatment, and metastasis is the major driver of death1–3. For better treatment of TNBC metastasis, it is urgent to understand the biological characteristics. The mechanisms of metastasis are complex, including the effects between tumor cells and microenvironment, the formation of circulating tumor cells (CTCs), the interaction with target organs before the implantation of CTCs, the circulating free DNA, and so on4–7.

Establishing a novel animal model is helpful to understand the mechanisms of TNBC metastasis8–9. Common animal models are unable to fully simulate the process of metastasis, mainly due to the lack of the microenvironment of normal human breast tissues and target organs10,11. Based on the NOD/SCID-hu system, our group established a novel mouse model, in which normal human breast and bone tissues were subcutaneously transplanted at different abdomens of a mouse12. After testing the biology of several human breast cancer cell lines in the model, we found that TNBC cell line SUM-1315 could spontaneously form species-specific bone metastasis, certifying the model.
MicroRNAs (miRNAs) expression profiling analyses of SUM-1315-br (derived from orthotopic breast tumor) and SUM-1315-bo (derived from metastatic bone tumor) were conducted. MiRNAs are a class of small non-coding RNAs that regulate gene expression. Comparing the differences in miRNAs expression profiling analyses of SUM-1315-br and SUM-1315-bo, key molecules promoting TNBC metastasis could be screened out.

In the study, the expression level of miR-1976 in SUM-1315-bo was found lower than that in SUM-1315-br. The evaluation of clinical TNBC specimens also showed that miR-1976 was downregulated in malignant tissues and lower expression of miR-1976 was associated with worse overall survival in a patient cohort obtained from TCGA database. The biological functions of miR-1976 in TNBC metastasis were investigated in vitro and in vivo, and further identified phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG) as a direct target gene of miR-1976. MiR-1976 knockdown promoted epithelial–mesenchymal transition (EMT) and cancer stem cell (CSC) properties by targeting PIK3CG in TNBC metastasis. Moreover, miR-1976 decreased the expression of PIK3CG and restoration of PIK3CG expression attenuated the inhibitory effects of miR-1976 on EMT and CSCs in TNBC. Thus, miR-1976 may serve as an anti-cancer metastatic biomarker with high efficacy.

**Methods**

**Clinical samples**

TNBC tissues and adjacent normal tissues (35 pairs) were obtained from the First Affiliated Hospital with Nanjing Medical University. All patients received no neoadjuvant therapy. The collected samples were frozen in liquid nitrogen immediately after resection. All patients provided written informed consent, and the study was approved by the Ethics Committee of the First Affiliated Hospital with Nanjing Medical University.

**Analysis of TCGA database**

The correlation between the expression level of miR-1976 and the overall survival of patients with TNBC was analyzed by Kaplan–Meier Plotter (https://kmplot.com/analysis/). Patients were separated by the auto select best cutoff, which was computed between the lower and upper quartiles and was the best performing threshold.

**Cell lines and culture condition**

Primary breast cancer cell lines (SUM-1315-br and SUM-1315-bo) were purified from orthotopic breast tumor and metastatic bone tumor respectively. SUM-1315 was kindly provided by Stephen Ethier (University of Michigan, Ann Arbor, MI, USA). Other human breast cancer cell lines (MDA-MB-231, ZR-75-1 and MCF-7) were obtained from the American Tissue Culture Collection (ATCC). All cell lines were cultured in Dulbecco’s modified Eagle medium (DMEM) medium (Gibco, Detroit, MI, USA) containing 10% fetal bovine serum (Gibco, Detroit, MI, USA) and 1% penicillin–streptomycin (Gibco, Detroit, MI, USA) at 37 °C with 5% CO2.

**Lentivirus and plasmid transfection**

The miR-1976 negative control, mimics and inhibitor lentiviruses were constructed by GenePharma (Shanghai, China) to change the expression level of miR-1976 in breast cancer cell lines. The transfection of lentiviruses was performed according to the respective MOI. Stable cell lines were selected by using 5 μg/ml puromycin (Sigma, USA). Plasmid of target gene PIK3CG was constructed by GenePharma (Shanghai, China). Cells were seeded into 6-well plates 1 day before plasmid transfection, and transfections were performed using Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer’s protocol.

**Cell wound-healing assay**

Cell wound-healing assay was used to evaluate cell migration. Cells were seeded in 6-well plates and a monolayer was scratched after incubation for 24 h. After washing three times with PBS, phase images were taken by inversion fluorescence microscopy at 0 and 48 h (Olympus, Japan). ImageJ software was used to measure the wound areas.

**Cellular transwell assay**

One-hundred microliters of cell suspension in serum-free DMEM was added to the upper chamber and 600 μl DMEM containing 10% fetal bovine serum was added to the lower chamber to induce cells to the other side of membrane. After incubation for 24 h, cells were collected to assess migration. When assessing invasion, membranes were coated with Matrigel (Corning, USA), and cells were collected after incubation for 48 h. Then cells that passed through the membrane were stained with crystal violet (Beyotime, Shanghai, China) for 30 min, and counted at a ×200 magnification in five randomly selected regions per well.

**Cell viability assay**

Cells were seeded at a density of 1 × 104/well in 96-well plates in triplicate and incubated for 24 h. Cell viability was assayed by CellTiter-Lumi™ Luminescence Cell Viability Assay Kit (Beyotime, Shanghai, China) based on quantification of adenosine triphosphate (ATP), which represented the number of active cells. Data were presented as relative viability by comparing with negative control, the viability of which is assumed to be 1.
Cell apoptosis analysis

Cell apoptosis rates were analyzed after transfection with miR-1976 mimics or inhibitors. Cells were collected after washing twice with PBS, and were stained with the Annexin V-APC/7-AAD apoptosis kit (MULTI SCIENCES, Hangzhou, China) for 5 min at room temperature. They were then evaluated by flow cytometry (BD Biosciences, USA).

Flow cytometry analysis

The expression levels of Ki-67, CD44 (Cluster of differentiation 44) and CD24 (Cluster of differentiation 24) were analyzed by flow cytometry.

Cells were dissociated using Trypsin Solution without EDTA (Beyotime, Shanghai, China) and resuspended in Flow Cytometry Staining buffer (MULTI SCIENCES, Hangzhou, China). Cells were stained with anti-human Ki-67 (BioLegend, USA) after permeabilization with 70% ethanol at −20 °C for 1 h. Data were compared by the mean of log fluorescence intensity. Cells were incubated with anti-human CD44-APC, anti-human CD24-PE and the APC and PE isotype control antibodies (eBioscience, USA) for 30 min at room temperature. Cells were washed and evaluated by flow cytometry (BD Biosciences, USA) to determine population distribution.

Mammosphere formation assay

Cell lines were plated in ultra-low attachment 6-well plates (Corning, USA) at a density of 5000/well in serum-free DMEM/F12 medium supplemented with B27 (Invitrogen), 20 ng/ml EGF (Invitrogen), and 20 ng/ml bFGF (BD Biosciences). After culturing for 7–14 days, mammospheres greater than 60 μm in diameter were counted under the microscope. Experiments were done in triplicates.

RNA extraction and quantitative real-time-polymerase chain reaction (qRT-PCR)

Total RNA was extracted by Trizol reagent (Takara, Japan) following the manufacturer’s protocol. For miRNA expression analysis, complementary DNA (cDNA) was specifically synthesized and miRNA was detected with Bulge-Loop™ miRNA qRT-PCR (Ribobio, Guangzhou, China). Relative expression level of miR-1976 was normalized to U6. For PIK3CG messenger RNA (mRNA) expression analysis, first strand cDNA was synthesized by PrimeScript™ RT Master Mix (Takara, Japan). PIK3CG mRNA expression was detected with TB Green™ Premix Ex Taq™ II (Takara, Japan) and normalized to GAPDH. The qRT-PCR reactions were performed in the ABI StepOne Plus (Applied Biosystems, Foster City, CA, USA) and the relative expression was calculated using the 2^−ΔΔct method. All procedures were performed in triplicate.

Western blotting

Protein was extracted from cells, electrophoresed on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. Then membranes were blocked in QuickBlock™ Blocking Buffer (Beyotime, Shanghai, China) for 15 min, and incubated in primary antibodies for 4 °C overnight. After washing with Tris Buffered saline Tween (TBST), the membranes were incubated in secondary antibodies for 2 h at room temperature. The primary antibodies included anti-E-cadherin, anti-N-cadherin, anti-Vimentin, anti-Snail, anti-Slug, anti-CD44, anti-PIK3CG, anti-AKT, anti-p-AKT and anti-GAPDH (diluted 1:1000, Cell Signaling Technology, USA). GAPDH was used as an internal control.

Transcriptome sequencing

Total RNA samples of SUM-1315 transfected with negative control and mimics lentiviruses were qualified by agarose gel electrophoresis and quantified by NanoDrop. The commercial kit (DECODE GENOMICS, Nanjing) for mRNA library preparation was used. The differentially expressed mRNAs were analyzed above the threshold level (1.5) and p-value was less than or equal to 0.05 between SUM-1315 transfected with negative control and mimics.

Biotinylated miRNA pull-down

SUM-1315 cell was transfected with the biotinylated negative control or mimics (Ribobio, Guangzhou, China), and digested 24 h after transfection. Before preparing lysate, crosslink was performed. Then mRNA was isolated from crude lysate by incubating with Streptavidin C1 (Invitrogen, USA) following the protocol. Then biotin-miRNA-mRNA were pulldown, and the RNA was extracted directly from the remaining beads with Trizol reagent (Takara, Japan).

Luciferase reporter assay

Possible binding sites between miR-1976 and 3’-UTR of PIK3CG were obtained from TargetScan. Wild-type PIK3CG plasmid (PIK3CG-3’-UTR-WT) and mutant PIK3CG plasmid (PIK3CG-3’-UTR-MUT) were purchased from Genechem (Shanghai, China). Cells were transfected with appropriate plasmid. Luciferase assays were measured by the Dual-luciferase reporter assay system after transfection 48 h (Promega, USA). Transcriptional activity was calculated as Luciferase activity/Renilla Luciferase activity.

Animal models

All animal experiments were approved by the Nanjing Medical University Institutional Animal Care and Use Committee and were carried out at the Animal Center. In total, two groups with ten 4-week-old female mice (BALB/c nude mice) per group were used for the construction of a tail vein metastasis model. In all, 1×10^6
cells (SUM-1315 miR-NC or SUM-1315 miR-mimics) were injected into the tail vein of each female nude mouse. All mice were euthanized after 4 weeks, and lungs were removed and fixed with 4% paraformaldehyde. Three sections were stained with hematoxylin-eosin (HE) to assess the presence of metastasis.

Immunohistochemical analyses (IHC)

Four-micrometer-thick sections were made from the formalin-fixed, paraffin-embedded blocks, which were then dried, deparaffinized, and rehydrated following the manufacturer’s protocol. The anti-E-cadherin, anti-N-cadherin, anti-Vimentin, and anti-CD44 incubation was carried out at room temperature for 1 h after antigen retrieval. The detections were conducted by standard avidin-biotin-peroxidase techniques. Immunohistochemical samples were assessed by two pathologists, and the staining intensity was defined as follows: weak (0); moderate (1); strong (2).

Statistical analysis

The statistical analysis was performed by SPSS software (Version 25.0) and GraphPad Prism (Version 8.0), and presented as mean ± standard deviation (SD). All data were analyzed by two-tailed Student’s t-test. Each experiment was repeated at least three times, and \( p < 0.05 \) was considered statistically significant.

Results

MiR-1976 was significantly downregulated in TNBC and acted as a prognostic factor

To identify differentially expressed miRNAs between SUM-1315-br and SUM-1315-bo, miRNA expression profiling analysis was performed. MiR-1976 was found significantly lower in SUM-1315-bo than that in SUM-1315-br, and the result was verified by qRT-PCR (Supplementary Fig. S1a). The expression levels of miR-1976 in TNBC cell lines (SUM-1315 and MDA-MB-231) were lower than those in hormone receptor-positive cell lines (ZR-75-1 and MCF-7) (Supplementary Fig. S1b). The expression levels of miR-1976 in 35 pairs of TNBC tissues and adjacent normal tissues were also examined by qRT-PCR, and the expression levels were markedly decreased in TNBC tissues (Fig. 1a). Clinical characteristics of individuals were shown in Supplementary Table S1. Data on miR-1976 were obtained from 97 patients with TNBC from the TCGA database and analyzed by Kaplan–Meier Plotter. The lower expression of miR-1976 was correlated with worse overall survival (68 high expression and 29 low expression, \( p = 0.039 \)), and the cutoff value was 9 and HR was 0.35 (95% CI 0.12–1) (Fig. 1b).

miR-1976 knockdown promoted EMT in vitro

TNBC cell lines (SUM-1315 and MDA-MB-231) were transfected with miR-1976 mimics lentivirus, and hormone receptor-positive cell lines (ZR-75-1 and MCF-7) were transfected with miR-1976 inhibitor lentivirus. The transfection efficiency was verified by qRT-PCR (Fig. 2a). Cell wound-healing assay and cellular transwell assay were used to assess the effects of miR-1976 on cell motility. As shown in Fig. 2b, the wound healing rate of SUM-1315 and MDA-MB-231 transfected with miR-1976 mimics was significantly decreased compared with negative control, while ZR-75-1 and MCF-7 transfected with miR-1976 inhibitor showed the opposite effects.
Fig. 2 (See legend on next page.)
Overexpression of miR-1976 reduced tumor metastasis in vivo

In order to investigate the effects of miR-1976 in vivo, SUM-1315 transfected with negative control and mimics lentiviruses were injected into the tail vein of female nude mice. After 4 weeks, all mice were euthanized, and lung tissues were removed for further investigation. Metastases were observed in two of ten mice injected with SUM-1315 miR-mimics, while eight of ten mice injected with negative control exhibited metastasis (Fig. 4a). Furthermore, IHC analyses of E-Cadherin, N-Cadherin, and Vimentin in the lung metastases were analyzed. The expression level of E-Cadherin in control group was weaker than that in the other group injected with miR-1976 mimics, while the expression levels of mesenchymal biomarkers (N-Cadherin and Vimentin) in the control group were markedly stronger (Fig. 4b). Similarly, the expression level of CD44 in control group was significantly stronger than those injected with miR-1976 mimics (Fig. 4c). These results indicated that overexpression of miR-1976 might reduce tumor metastasis by inhibiting EMT and CSCs in vivo.

**PIK3CG was a direct downstream target of miR-1976**

To explore the underlying mechanisms of miR-1976, transcriptome sequencing of SUM-1315 transfected with negative control and mimics lentiviruses was performed, and genes with an absolute fold change (FC) > 1.5 and p-value ≤ 0.05 were selected (Fig. 5a). Three publicly available bioinformatics algorithms (TargetScan, miRWalk, and DIANA) were used to predict target genes, and 3 genes were overlapped (Fig. 5b). The 3’-end biotinylated negative control and mimics were transfected into SUM-1315 cells. After streptavidin capture, the mRNA levels of PIK3CG, FMNL3, THOC5 and GAPDH were quantified by qRT-PCR, and the relative immunoprecipitate/input ratios were plotted (Fig. 5c). Furthermore, according the mRNA expression profiling analysis of SUM-1315-br and SUM-1315-bo, the expression level of PIK3CG in SUM-1315-bo was higher than that in SUM-1315-br. The protein and mRNA expression of PIK3CG were also verified by western blot and qRT-PCR (Fig. 5d, e).

PIK3CG was identified as a potential target gene of miR-1976, and possible binding site was obtained from database (Fig. 5f). Luciferase reporter assay was constructed that had either a PIK3CG-3’-UTR-WT or PIK3CG-3’-UTR-MUT sequence of the miR-1976-binding site. The relative luciferase activities were decreased after transfected with miR-1976 mimics and PIK3CG-3’-UTR-WT in SUM-1315 and MDA-MB-231.
cells, while the luciferase activities were not decreased after transfected with PIK3CG-3'-UTR-MUT (Fig. 5g).

The protein expression levels of PIK3CG, AKT and p-AKT (a downstream) were measured in SUM-1315 and MDA-MB-231 transfected with miR-1976 mimics by western blot, and the levels were reduced (Fig. 5h). The mRNA expression level of PIK3CG was measured by qRT-PCR, and the level was reduced after SUM-1315 and MDA-MB-231 transfected with miR-1976 mimics (Fig. 5i). Overall, miR-1976 mimics decreased mRNA and

Fig. 3 MiR-1976 knockdown changed CSC properties. a The expression levels of CD44 and CD24 in cells transfected with miR-1976 mimics and inhibitor respectively were analyzed by flow cytometry analysis. Cells were stained with anti-CD44-APC and anti-CD24-PE. Overexpression of miR-1976 decreased the populations of CD44+/CD24− in SUM-1315 and MDA-MB-231, and miR-1976 knockdown increased the populations of CD44+/CD24− in ZR-75-1 and MCF-7. b Mammosphere formation assay was performed, and the representative pictures were shown. Scale bar: 100 μm. c Western blot analysis showed that miR-1976 reduced the protein expression level of CD44 in SUM-1315 and MDA-MB-231, and miR-1976 inhibitors increased the level in ZR-75-1 and MCF-7. *p < 0.05, **p < 0.01, ***p < 0.001. The data expressed as the mean ± SD.
protein expression level of PIK3CG, and it suggested that PIK3CG might be a direct target of miR-1976 and that its expression level was negatively regulated by miR-1976.

**Overexpression of PIK3CG accounted for function of miR-1976**

To further investigate whether the effects of miR-1976 on EMT and CSCs were mediated by PIK3CG, the expression level of PIK3CG was upregulated by PIK3CG plasmid (p-PIK3CG) and downregulated by PIK3CG inhibitor, CAY10505 (MedChemExpress). As expected, miR-1976 mimics reduced the mRNA and protein level of PIK3CG in SUM-1315 cells, and this effect was reversed by p-PIK3CG, while miR-1976 inhibitor increased the mRNA and protein level of PIK3CG in ZR-75-1 cells, and this effect was reversed by CAY10505 (Fig. 6a, b). The wound healing assay and transwell assay were performed, and we found that p-PIK3CG could attenuate the inhibitory effect of miR-1976 in EMT, and CAY10505 could suppress the effects (Fig. 6c, d). The expression levels of the epithelial marker, mesenchymal markers, and transcription factors in SUM-1315 affected by miR-1976 mimics were reversed by p-PIK3CG. In addition, CAY10505, PIK3CG inhibitor, could reverse the effects of miR-1976 inhibitor in ZR-75-1 cells (Fig. 6e). The effects of PIK3CG on proliferation and cell death were also analyzed. p-PIK3CG promoted cell proliferation and reduced cell apoptosis, and CAY10505 suppressed cell proliferation and induced cell apoptosis (Supplementary Fig. S4).

Similarly, p-PIK3CG could markedly increase the populations of CD44+/CD24− and the number of mammospheres in SUM-1315 cells transfected with miR-1976 mimics. In ZR-75-1 cells transfected with miR-1976 inhibitor, CAY10505 could partially reduce the populations and the number of mammospheres (Fig. 6f, g). Consistently, p-PIK3CG upregulated the protein expression of CD44 in SUM-1315 cells transfected with miR-1976 mimics, and CAY10505 reduced the expression level in ZR-75-1 cells transfected with miR-1976 inhibitor (Fig. 6h). Taken together, it suggested that miR-1976
exerted its antitumor effects in TNBC by targeting PIK3CG, and PIK3CG could be a functional target of it.

**Discussion**

TNBC is defined as the subtype lacking the expression of ER, PR, and HER2\textsuperscript{14}, and lacks effective targeted therapy, so the prognosis of TNBC is worse than other subtypes. Metastasis is the primary cause of death in TNBC patients, and a great challenge in clinical treatment\textsuperscript{1}. In 1889, Stephen Paget proposed the “seed and soil” hypothesis, and thought that tumor metastasis was the result of the development of metastatic tumor cells.
(See legend on next page.)
(seeds) in the target organs (soil)\textsuperscript{15,16}. The interactions between tumor cells and target organs play an important role in metastasis, that is, metastasis is a two-sided function. We established a novel mouse model containing normal human breast and bone tissues\textsuperscript{12}. This model simulated the microenvironment of TNBC metastasis in human, including the microenvironment of local tumor and target organs. We compared the different miRNA expression between SUM-1315-br and SUM-1315-bo, and miR-1976 was selected and verified in clinical tissues and databases.

Previous studies have described the role of miR-1976 in non-small cell lung cancer, functioning as a tumor suppressor and serving as a prognostic indicator\textsuperscript{17}. However, very little was known about the biological effects on TNBC. We explored it and found that miR-1976 knockdown significantly increased the wound healing rate and cell migration, promoted proliferation, reduced cell apoptosis, and enhanced the populations of CD44\textsuperscript{+}/CD24\textsuperscript{−} in vitro. Moreover, miR-1976 inhibitors downregulated the epithelial marker, E-Cadherin, and upregulated mesenchymal markers and transcription factors, N-Cadherin, Vimentin, Snail and Slug. The effects of miR-1976 on proliferation and cell death could contribute to the results in EMT and CSCs. These effects were also verified in vivo. We adopted two different experimental animal models to study the roles of miR-1976 in tumor metastasis. The metastatic model was used to simulate human microenvironment and screen different indicators, while the tail vein injection model was a general model in researching tumor metastasis\textsuperscript{18,19}. Immunohistochemical analyses of EMT markers and CD44 in the lung metastases were analyzed. The expression levels of E-Cadherin in the control group were significantly lower than those injected with miR-1976 mimics, while the expression levels of N-Cadherin, Vimentin, and CD44 were markedly higher. Taken together, these results indicated that miR-1976 acted as a suppressor miRNA, exerting an important effect on TNBC progression.

MiR-1976 knockdown markedly promoted migration and invasion, acquiring aggressive traits and strengthening mesenchymal properties. Mesenchymal cells infiltrate into distant organs and then transit into epithelial cells to form macroscopic metastatic foci. EMT enables the steps of metastasis, including local invasion and dissemination to target organs\textsuperscript{20,21}. Several studies have shown that EMT could accelerate progression by the increase of proliferation, suppression of apoptosis, induction of cancer stem cells, augmented angiogenesis, and immunosuppression\textsuperscript{22,23}. Metastasis on target organs is thought to be associated with self-renewal\textsuperscript{24,25}. CSCs are a small group of tumor cells with self-renewal and differentiation capability similar as normal stem cells, reproducing the heterogeneity of original tumors\textsuperscript{26–28}. Accumulating evidences have revealed that CSCs have long-term proliferative potential and are important mediators of tumor metastasis and cancer relapse\textsuperscript{29}. CD44 and CD24 are the most common CSC markers in breast cancer\textsuperscript{30}, and CD44\textsuperscript{+} and CD24\textsuperscript{−/low} are associated with anti-cancer drug resistance, tumor recurrence, and metastasis. In our study, we found miR-1976 knockdown markedly promoted EMT and CSC properties.

PIK3CG was screened as a target gene of miR-1976 by biotinylated miRNA capture, and verified by luciferase reporter assay. Overexpression of PIK3CG counteracted the inhibition effect of miR-1976 mimics on EMT and CSC properties, and PIK3CG inhibitor CAY10505 could reverse the effects of miR-1976 inhibitor. MiR-1976 regulated the expression level of PIK3CG via binding to the 3'UTR of the mRNAs resulting in post-transcriptional repression or degradation. PIK3CG is considered as a cancer-promoting gene in a variety of tumors, and it has been reported that PIK3CG promoted metastasis and invasion\textsuperscript{31,32}. At present, the potential targets of TNBC are mainly abnormal signal transduction pathways or overexpressed proteins, such as mTOR (mammalian target of rapamycin) inhibitors everolimus\textsuperscript{33}, which has been used in clinical trials. MTOR is an important protein kinase and is a downstream of PI3K/Akt signaling pathway that regulates the proliferation, invasion and metastasis by activating ribosomal kinases. Our results suggested that PIK3CG inhibitor may also be a treatment target for TNBC metastasis, achieving similar effects to mTOR inhibitor.

In conclusion, we have identified that miR-1976 was downregulated in TNBC. MiR-1976 knockdown induced TNBC metastasis by promoting EMT and CSCs. These effects of miR-1976 were dependent on its direct regulation...
of PIK3CG. These findings may reveal mechanisms of TNBC metastasis, and represent a potential treatment target for patients with TNBC.

Acknowledgements

We thank Dr. Stephen Ether for providing breast cancer cells and all patients for participating in this study. This study was funded by the Natural Science Foundation of China (81572607) and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX19_1158).

Author contributions

S.W., T.X., and G.M. has contributed to the design of the study, the interpretation of data, the revision of the article as well as final approval of the version to be submitted. J.W., M.L., and X.H. participated in the design of the study, performed the statistical analysis, and drafted and revised the article. J.W., M.L., X.H., H.W., and X.W. performed the experimental study. All authors read and approved the final version of the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

accompanies this paper at (https://doi.org/10.1038/s41419-020-2711-x).

Received: 8 February 2020 Revised: 28 May 2020 Accepted: 29 May 2020

Published online: 03 July 2020

References

1. Foulkes, W. D., Smith, I. E. & Res-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–194 (2010).
2. Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429–4434 (2007).
3. Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275–1281 (2008).
4. Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275–292 (2011).
5. Kolb, A. D., Shupp, A. B., Mukhopadhyay, D., Marin, F. C. & Bussard, K. M. Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 31, 219 (2019).
6. Alik-Panabieres, C., Schwarzenbach, H. & Pantel, K. Circulating tumor cells and circulating tumor DNA. Annu. Rev. Med. 63, 199–215 (2012).
7. Ma, G. et al. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer. Cancer Med. 9, 2271–2282 (2020).
8. Byrne, H. M. Dissecting cancer through mathematics: from the cell to the animal model. Nat. Rev. Cancer 10, 221–230 (2010).
9. Le Magnen, C., Dutta, A. & Abate-Shen, C. Optimizing mouse models for precision cancer prevention. Nat. Rev. Cancer 16, 187–196 (2016).
10. Kamb, A. What’s wrong with our cancer models? Nat. Rev. Drug Discov. 4, 161–165 (2005).
11. Mbalaviele, G. et al. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res. 56, 4063–4070 (1996).
12. Xia, T. S. et al. Bone metastasis in a novel breast cancer mouse model containing human breast and human bone. Breast Cancer Res. Treat. 132, 471–486 (2012).
13. Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–789 (2010).
14. Guiz, O. et al. Triple-negative breast cancers—are current status and future directions. Ann. Oncol. 20, 1913–1927 (2009).
15. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98–101 (1989).
16. Fidler, I. J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat. Rev. Cancer 3, 453–458 (2003).
17. Chen, G., Hu, J., Huang, Z., Yang, L. & Chen, M. MicroRNA-1976 functions as a tumor suppressor and serves as a prognostic indicator in non-small cell lung cancer by directly targeting PLCE1. Biochem. Biophys. Res. Commun. 473, 1144–1151 (2016).
18. Bonin, T. F. et al. Melatonin decreases breast cancer metastasis by modulating Rhoa-associated kinase protein-1 expression. J. Pineal Res. 60, 3–15 (2016).
19. Wang, Q. et al. Tamoxifen enhances stemness and promotes metastasis of ERα/ERβ + breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 28, 336–358 (2018).
20. Brabletz, T., Kalluri, R., Nieto, M. A. & Weinberg, R. A. EMT in cancer. Nat. Rev. Cancer 18, 128–134 (2018).
21. Pastushenko, I. et al. Identification of the tumour transition states occurring during EMT. Nature 556, 463–468 (2018).
22. Bouris, P. et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 43, 62–69 (2015).
23. Sanchez-Tillo, E. et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mast cell lymphoma. Cell Death Differ. 21, 247–257 (2014).
24. Scheel, C. & Weinberg, R. A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 22, 396–403 (2012).
25. Rollè, S. et al. The epithelial-to-mesenchymal transition: a coalition against cancer therapies. J. Mammary Gland Biol. Neoplasia 14, 29–43 (2009).
26. Fleming, A. Cancer stem cells: targeting the root of cancer relapse. Nat. Rev. Drug Discov. 14, 165 (2015).
27. Delude, C. Tumorigenesis: testing ground for cancer stem cells. Nature 480, 543–545 (2011).
28. Dittmer, J. Breast cancer stem cells: features, key drivers and treatment options. Semin. Cancer Biol. 25, 59–74 (2015).
29. Ma, F. et al. Enriched CD44(+)/CD24(-) population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Res. 75, 153–159 (2014).
30. Shipton, M. et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259–273 (2007).
31. Zhang, S. et al. Ectopic fringes promote a claudin-low breast cancer phenotype through notch-mediated PIK3CG induction. Cancer Res. 75, 1936–1943 (2015).
32. Wang, X. et al. Hypoxic tumor-derived exosomal miR-301a mediates M2 macrophage polarization via PI3K/Akt5/alpha5 to promote pancreatic cancer metastasis. Cancer Res. 78, 4586–4598 (2018).
33. Basho, R. K. et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in combination with liposomal doxorubicin and bev-acizumab. JAMA Oncol. 3, 509–515 (2017).